Skip to main content

Table 1 Demographic data and symptoms in PD patients involved in this study

From: Association between NMD3 and symptoms of Parkinson’s disease in Chinese patients

 

NMD3 carriers (n = 178)

NMD3 wildtypes (n = 39)

p value

Age, mean (SD)

57.03 (10.16)

55.69 (10.24)

0.461

Gender, female, N (%)

73 (41.01)

17 (43.59)

0.907

Disease duration, mean (SD)

4.79 (4.28)

5.56 (3.89)

0.275

Family history, N (%)

17 (9.55)

5 (12.82)

0.550

Hoehn – Yahr staging, N (%)

  

0.869

 1.0

41 (23.03)

10 (25.64)

 

 1.5

29 (16.29)

4 (10.26)

 

 2.0

60 (33.71)

14 (35.90)

 

 2.5

32 (17.98)

7 (17.95)

 

 3.0

12 (6.74)

4 (10.26)

 

 4.0

4 (2.24)

0 (0.00)

 

 5.0

0 (0.00)

0 (0.00)

 

MDS-UPDRS, mean (SD)

48.34 (27.10)

43.05 (20.51)

0.175

 Part I

8.66 (6.16)

7.51 (5.43)

0.249

 Part II

11.60 (7.71)

10.08 (5.81)

0.168

 Part III

28.08 (17.45)

25.46 (14.10)

0.318

NMSS, mean (SD)

36.23 (35.57)

31.03 (27.42)

0.315

SCOPA-AUT, mean (SD)

10.92 (9.06)

9.08 (8.56)

0.233

PDQ-39, mean (SD)

19.31 (17.84)

16.23 (13.93)

0.241

MMSE, mean (SD)

26.31 (3.79)

27.44 (2.89)

0.042

MoCA, mean (SD)

20.75 (6.68)

23.15 (4.20)

0.005

  1. MDS, movement disorders society; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; NMSS, non-motor symptoms scale; SCOPA-AUT, scales for Outcomes in Parkinson’s disease – autonomic questionnaire; SD, standard deviation; PD, Parkinson’s disease; PDQ-39, 39-item Parkinson’s disease Questionnaire; UPDRS, unified Parkinson’s disease rating scale